LEXINGTON, Mass., April 19, 2017 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that the company will be hosting a special symposium highlighting the clinical and economic benefits of testing with the T2Candida® Panel and previewing the performance of the T2Bacteria™ Panel at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria on Saturday, April 22. ECCMID is an annual conference that brings together leading experts to discuss the latest developments in infectious disease, infection control and clinical microbiology.
At the symposium, leading experts from several U.S. and European hospitals will discuss how the FDA-cleared and CE-marked T2Candida Panel is delivering significant improvements in patient outcomes in conjunction with substantial economic savings. In addition, early performance data from T2Bacteria Panel and our sepsis product pipeline will be shared, highlighting the promise to deliver the same significant benefits of rapid and highly sensitive direct-from-blood detection as T2Candida.
Maurizio Sanguinetti, MD, Policlinico Universitario Agostino Gemelli, Rome, Italy
Proven Clinical Benefit and Economic Savings of T2Candida in Hospital Practice
Sandy J. Estrada, Pharm.D., BCPS, Lee Health System, Florida, USA
T2Candida – Impactful Case Study Reviews
Patricia Muñoz, MD, PhD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Early Experience with T2Bacteria – Direct-from-Blood Species Identification
Giulia De Angelis, MD, Policlinico Universitario Agostino Gemelli, Rome, Italy
The Future of Rapid, Direct-from-Blood Sepsis Diagnostics
Rahul Dhanda, T2 Biosystems, Massachusetts, USA
Saturday 22 April 2017
13:30 – 15:30pm
Reed Messe Wien GmbH (HALL C)
Messeplatz 1, Postfach 277
Be sure to follow all T2 specific developments and news from the #ECCMID2017 conference on Twitter via the T2 Biosystems handle @T2Bio.
Media interested in one-on-one interviews live or by phone before or after the T2 symposium should contact the T2 press coordinators below to set up an interview.
Click here for highlights of IDWeek 2016 hospital data detailing improvements in patient care and hospital savings from T2Candida.
In addition, T2 Biosystems will be presenting a poster on the T2Lyme Panel:
P0342. “Direct detection of early-stage Lyme borreliosis using T2 magnetic resonance”
Session: Challenges in diagnostic bacteriology
Presenter: T2 Biosystems
Date: Saturday, 22 April 2017
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
CONTACT: Media Contacts: Amy Crosby, T2 Biosystems email@example.com +1 (978) 478-8451 On-site contact Matthew McKillip, T2 Biosystems firstname.lastname@example.org +1 (518) 577-3466 Investor Contact: Tucker Elcock, Teneo Strategy Tucker.Elcock@teneostrategy.com +1 (212) 886-9319